The purchase price, and that is confidential and was negotiated for a maximum of 300 million doses, is somewhat less than the $19.50 per picture the United States agreed to pay for a very first shipment of hundred million doses of the identical vaccine, in series with what Reuters claimed in November.
The EU booklet dated Nov. 18 was circulated internally right after the EU announced its supply offer with Pfizer and its German partner BioNTech on Nov. 11.
The EU drug regulator is actually expected to decide on Monday on acceptance for the Pfizer vaccine after the photo was authorised in a few countries, like Britain as well as the United States.
On Thursday Belgian state secretary for the budget Eva De Bleeker released on Twitter a table with costs Belgium will spend pharmaceutical companies for the COVID 19 vaccines of theirs. She retracted the post shortly after posting.
In that dinner table the Pfizer vaccine was indicated as costing Belgium twelve euros ($14.6) a dose, leading many to think that was the entire price agreed by way of the EU.
Other vaccines in the family table were also shown with prices lower compared to rates disclosed by EU solutions.
“There is surely a total cost along with a price after delivery,” an EU official involved in talks with vaccine makers told Reuters when asked to clarify the big difference between the EU and Belgian rates.
A spokesman for De Bleeker declined to comment on Monday, citing confidentiality requirements, but pointed to what De Bleeker told the Belgian parliament last week. In that public hearing, De Beeker stated Belgium’s budgeted prices were still partial.
Under EU advance purchase deals for COVID 19 vaccines, the bloc concurs upfront payments with business enterprises to secure doses before they’re approved. After approvals, EU governments can pay the remainder to purchase reserved doses.
The EU has not revealed the upfront payment agreed with Pfizer.
But, it mentioned in October that it paid about one billion euros inside downpayments to AstraZeneca, Sanofi and Johnson & Johnson for their shots, with an additional 1.45 billion euros budgeted for upfront payments to Pfizer-BioNTech, Moderna and Curevac.
It’s since agreed supply deals with all 6 corporations and it is negotiating a seventh understanding with Novavax.